Dr. Reddy’s Laboratory has announced the launch of Remidesivir under the brand name Redyx in India. The launch is part of a licensing agreement with Gilead Sciences Inc that grants Reddy’s the right to register, manufacture and sell Remidesivir.
Remidesiver is a potential treatment for COVID-19 and is approved by Drug Controller General of India (DCGI) for restricted emergency use in India for the treatment of patients with severe COVID-19 symptoms.
Dr Reddy Redyx is available in the strength of 100 mg vial.
Addressing the launch, Chief Executive Officer for branded markets at Dr Reddy’s, M V Ramana said “Wewill continue our efforts to develop products that address significant unmet needs of patients. The launch of Redyx reaffirms our commitment to bringing in critical medicine for patients suffering from COVID-19 in India.”
Last month, Hyderabad based Reddy’s Laboratories had launched Favipiravir 200 mg tablets under the brand name of Avigan in India.
